Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Drug Stores and Others) & Region for 2024 to ...

The researchers hoped the canines could unlock a treatment for human narcolepsy. They began laying out a path of dog kibble, then injecting the dogs with drugs such as selective serotonin reuptake ...

Find effective medications for 'Narcolepsy treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

This novel drug is intended for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric narcolepsy patients aged six and older. The FDA’s decision fast-tracks the ...

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

A collection of common and new medications is showing good results against the constellation of symptoms that individualize ...

Michael Thorpy, director of the Sleep-Wake Disorders Center at the Montefiore Medical Center, said: “Clinical evidence continues to support AXS-12 as a novel treatment option for narcolepsy that ...

Perceived social support was significantly lower among individuals with idiopathic hypersomnia or narcolepsy type 2 compared with narcolepsy type 1.

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

ENCORE was a multi-center, two-period Phase 3 trial evaluating the long-term efficacy and safety of AXS-12 in patients with narcolepsy with cataplexy, consisting of a 6-month open-label AXS-12 ...